Post-earnings recap
Reported
Tue, Aug 8, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss per share of $0.65, which was a slight miss compared to expectations. The stock reacted negatively, declining by 0.74%. The lack of revenue figures and forward guidance may have contributed to investor uncertainty, leading to the stock's downward movement.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.65 | N/A | -0.78% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook for the future, emphasizing the importance of their clinical programs. They did not provide specific guidance, which may leave investors uncertain.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on its ongoing clinical trials and product development.